Aflibercept

Aflibercept
Clinical data
Trade names	Eylea, Zaltrap
Other names	ziv-aflibercept
Biosimilars	aflibercept-abzv, aflibercept-ayyh, aflibercept-jbvf, aflibercept-mrbb, aflibercept-yszy, Ahzantive, Baiama, Enzeevu, Eydenzelt, Opuviz, Pavblu, Yesafili
AHFS/Drugs.com	Aflibercept Monograph; Ziv-aflibercept Monograph;
MedlinePlus	a612004
License data	US DailyMed: Aflibercept;
Pregnancy; category	AU: D; Not recommended;
Routes of; administration	Intravenous, intravitreal injection
Drug class	Antineovascularization agent
ATC code	L01XX44 (WHO) S01LA05 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	862111-32-8 ;
DrugBank	DB08885 ;
ChemSpider	none;
UNII	15C2VL427D;
KEGG	D09574 ;
ChEMBL	ChEMBL1742982;
Chemical and physical data
Formula	C4318H6788N1164O1304S32
Molar mass	96898.57 g·mol−1
	(what is this?) (verify)

Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals.

It is an inhibitor of vascular endothelial growth factor (VEGF). Aflibercept is a recombinant fusion protein consisting of the extracellular domains of human VEGF receptor 1 and 2 fused to the Fc portion of human IgG1. By acting as a soluble decoy for the natural VEGF receptors, aflibercept inhibits their activation, thereby reducing angiogenesis.